Adagio Medical Holdings, Inc (ADGM)

Adagio Medical Holdings, Inc.'s stock price has experienced significant fluctuations over the past six months. As of May 5, 2026, the share price was $0.98, a 22.22% decline from $1.26 on May 6, 2025, with a 52-week range between $0.74 and $2.58. In January 2025, the company announced waivers with investors following a financial misstatement and received a Nasdaq non-compliance notice, coinciding with a 90% stock decline. In late 2025, Adagio Medical completed enrollment for its FULCRUM-VT study, reported preliminary effectiveness results of 97%, and announced a private placement of up to $50 million. In April 2026, the company announced positive pivotal results for its vCLAS Ventricular Ablation System, received FDA IDE approval for its next-generation vCLAS, and participated in healthcare conferences.

There is no specific information available indicating demand seasonality for Adagio Medical Holdings, Inc.'s products and services. Demand is generally driven by patient needs and medical advancements rather than seasonal patterns.

Adagio Medical Holdings, Inc. is a medical device company focused on ablation technologies for cardiac arrhythmias, operating in the Healthcare sector, specifically in the Biotechnology & Drugs and Health Care Equipment industries. The company's primary focus is on catheter-based ultra-low temperature ablation (ULTA) technology, addressing various cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia (VT). Key products include the iCLAS atrial ULTC catheter and accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter and accessories. The ULTA products for VT are engineered to create durable, deep lesions within the ventricle through a stable, endocardial approach without requiring irrigation.

Adagio Medical Holdings, Inc. is headquartered in Laguna Hills, California, United States. The company's strategic focus for market expansion includes North American and European companies within the life sciences and medical technology sectors. Adagio Medical is actively involved in developing and placing its innovative ablation technologies on the EU market.

Adagio Medical Holdings, Inc.'s brand reputation has been influenced by positive developments in its product pipeline and challenges related to financial reporting and corporate governance. Positive events include the announcement of positive pivotal results for the vCLAS Ventricular Ablation System, FDA IDE approval for its next-generation vCLAS, and publication of pre-clinical results for its next-generation ULTA ventricular ablation catheter. Negative events include the disclosure of financial misstatements, subsequent waivers with investors, and a non-compliance notice from Nasdaq regarding audit committee requirements.

Adagio Medical Holdings, Inc. has significant institutional ownership, with 48.08% of its stock held by institutional investors, totaling 16,580,576 shares as of May 6, 2026. Major institutional owners include Perceptive Advisors LLC, Sio Capital Management, LLC, and Adage Capital Partners GP, L.L.C., among others. CEO & Director Todd Usen made a significant insider purchase of 207,315 shares for an estimated $225,973 in the past six months.